These are this Monday’s top analyst upgrades, downgrades and initiations.
Epizyme Inc. (NASDAQ: EPZM) was started as Outperform with a price target of $40 (versus a $22.71 close) at RBC Capital Markets. While this is a call to nearly double, Epizyme has a consensus price target of $38.67 and a 52-week range of $15.51 to $40.98.
Goldcorp Inc. (NYSE: GG) was started as Outperform with a price target of $24 (versus a $16.18 close) at Credit Suisse. Goldcorp has a consensus analyst target price of $24.19 and a 52-week range of $15.77 to $29.65.
GoPro Inc. (NASDAQ: GPRO) was started as Neutral with a price target of $60 (versus a $51.75 close) at Goldman Sachs. GoPro has a consensus price target of $69.25 and a 52-week range of $36.10 to $98.47.
Intuitive Surgical Inc. (NASDAQ: ISRG) was downgraded to Underweight from Equal Weight at Morgan Stanley, and the price target was cut to $500 from $560 (versus a $486.29 close). Intuitive Surgical has a consensus price target of $567.88 and a 52-week range of $376.00 to $559.04.
VMware Inc. (NYSE: VMW) Was downgraded to Market Perform from Outperform with a $90 price target (versus a $85.20 close) at FBR Capital Markets. VMware has a consensus analyst target of $96.10 and a 52-week range of $73.65 to $103.86.
ALSO READ: Why Investors and Analysts See AT&T as the Best Carrier Again
Other key analyst upgrades and downgrades this Monday were seen as follows:
Aetna Inc. (NYSE: AET) was downgraded to Market Perform from Outperform at FBR Capital Markets.
Axovant Sciences Ltd. (NASDAQ: AXON) was started as Buy with a target price of $31 (versus a $19.26 close) at Jefferies.
Biotie Therapies Corp. (NASDAQ: BITI) was started as Outperform with a price target of $35 (versus a $18.39 close) at RBC Capital Markets. Stifel also started it as Buy with a $30 price target.
Bunge Ltd. (NYSE: BG) was downgraded to Market Perform from Outperform with a $94.00 (versus a $89.52 close) at BMO Capital Markets.
Celanese Corp. (NYSE: CE) was downgraded to Neutral from Buy to Neutral at UBS.
CIRCOR International Inc. (NYSE: CIR) was downgraded to Sector Weight from Overweight at KeyBanc Capital Markets.
ALSO READ: 5 Oil and Gas Stocks Analysts Want You to Buy Now
Columbia Pipeline Group Inc. (NYSE: CPGX) was started as Buy with a target price of $33 (versus $30.34 close) at UBS.
Chemours Co. (NYSE: CC) was started with an Overweight rating and a $24 price target (versus a $16.51 close) at Barclays.
Chubb Corp. (NYSE: CB) was raised to Outperform from Market Perform at Keefe Bruyette & Woods.
Edwards Lifesciences Corp. (NYSE: EW) was raised to Overweight from Equal Weight with a price target of $168 (versus a $142.45 close) at Morgan Stanley.
EnLink Midstream Partners L.P. (NYSE: ENLK) was started as Buy with a target price of $27 (versus a $22.25 close) at UBS.
Humana Inc. (NYSE: HUM) was downgraded to Neutral from Outperform at Wedbush Securities.
NetSuite Inc. (NYSE: N) was downgraded to Underweight from Neutral with a $79 price target (versus a $91.66 close) at Piper Jaffray.
Penn National Gaming Inc. (NASDAQ: PENN) was reiterated as Buy with a $19 fair value estimate (versus a $18.35 close) at Janney Capital Markets.
ALSO READ: Deutsche Bank Loves 4 High-Yield Utilities
Raptor Pharmaceuticals Corp. (NASDAQ: RPTP) was downgraded to Underperform from Perform with a price target of $8.00 (versus a $15.79 close) at Oppenheimer.
Second Sight Medical Inc. (NASDAQ: EYES) was started as Buy with a $21 price target (versus a $14.05 close) at H.C. Wainwright.
Teekay LNG Partners L.P. (NYSE: TGP) was started as Overweight at JPMorgan.
Union Pacific Corp. (NYSE: UNP) was raised to Outperform at Cowen, noting that the stock’s weakness has gone on enough.
In case you missed last Thursday’s top analyst upgrades and downgrades, they included AT&T, Capstone Turbine, ConAgra Foods, Diamond Offshore Drilling, Hecla Mining and a dozen or so more.
Top Gaining Stocks
Top Losing Stocks